Abhyankar A, Prajapati J, Reddy S, Reddy S
Shree B.D. Mehta Mahavir Heart Institute Athwagate, Surat, India.
Minerva Cardioangiol. 2013 Jun;61(3):313-22.
The aim of this study was to evaluate the strut apposition and neointimal coverage of Supralimus-Core stent struts at 4 months after implantation using optical coherence tomography (OCT).
The Supralimus-Core OCT study is a retrospective, single-center study evaluating strut apposition and neointimal coverage with OCT at 4 months after stent implantation. A total of 12 patients, who had 15 stents implanted were included in the study. The OCT was obtained using a C7-XR FD-OCT (frequency-domain OCT) intravascular imaging system. Strut apposition, neointimal hyperplasia (NIH) thickness and stent coverage on each stent strut were evaluated.
A total of 2870 struts and 1950 frames were analyzed from 15 stents. Average stent length was 29.3 mm. Average reference vessel diameter was 2.64 mm. Among 12 patients, 3 (25.0%) patients were with diabetes, 4 (26.7%) type B2 and 10 (66.7%) type C lesions. The apposed and covered struts were 2787 (97.11%), whereas malapposed and covered struts were 3 (0.10%), apposed and uncovered 49 (1.71%) and malapposed and uncovered 31 (1.08%). Mean NIH thickness was 155.1±55.2 µm.
The present study suggests that Supralimus-Core stent has a favorable vascular healing pattern at 4 months after stent implantation in terms of stent-strut coverage and strut apposition. This information indicates that the Supralimus-Core stent is a promising solution for decreasing late stent restenosis and preventing stent thrombosis.
本研究旨在使用光学相干断层扫描(OCT)评估植入后4个月时Supralimus-Core支架支柱的贴壁情况和新生内膜覆盖情况。
Supralimus-Core OCT研究是一项回顾性单中心研究,评估支架植入后4个月时OCT下的支柱贴壁情况和新生内膜覆盖情况。共有12例植入了15枚支架的患者纳入本研究。使用C7-XR FD-OCT(频域OCT)血管内成像系统获取OCT图像。评估每个支架支柱的支柱贴壁情况、新生内膜增生(NIH)厚度和支架覆盖情况。
对15枚支架共分析了2870个支柱和1950个帧。平均支架长度为29.3毫米。平均参考血管直径为2.64毫米。12例患者中,3例(25.0%)患有糖尿病,4例(26.7%)为B2型病变,10例(66.7%)为C型病变。贴壁且覆盖的支柱为2787个(97.11%),贴壁但未覆盖的支柱为3个(0.10%),未贴壁但覆盖的支柱为49个(1.71%),未贴壁且未覆盖的支柱为31个(1.08%)。平均NIH厚度为155.1±55.2微米。
本研究表明,就支架支柱覆盖和支柱贴壁情况而言,Supralimus-Core支架在植入后4个月时具有良好的血管愈合模式。这一信息表明,Supralimus-Core支架是减少晚期支架再狭窄和预防支架血栓形成的一种有前景的解决方案。